Clene (CLNN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CLNN Clene

Watchlist

4.4000
+0.1000+2.33%

Close Dec 20 16:00 ET

4.4000
0.00000.00%

Post 16:06 ET

35.11MMarket Cap-0.83P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Clene Secures $10M Debt Facility to Enhance Position
TipRanksDec 20 17:30 ET
Express News | Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay off Existing Senior Loan
ReutersDec 19 08:00 ET
Press Release: Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Dow JonesDec 19 08:00 ET
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsDec 11 15:31 ET · Ratings
Promising Prospects for Clene's ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory Progress
TipRanksDec 11 14:35 ET
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway
Yahoo FinanceDec 11 11:15 ET

Comments

Trytosaveabit

Dec 10 13:21

New 425B ( Prospectus )

$Clene (CLNN.US)$ (((((((. Clene Inc. has entered into an equity distribution agreement to offer and sell up to $7.39 million of common stock through Canaccord Genuity. The at-the-market offering will be used to fund clinical development of CNM-Au8, Clene's lead drug candidate for neurological disorders like ALS and MS.
The company recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS. Clene plans to provide additional biomark...

Trytosaveabit

Dec 10 07:34

News

$Clene (CLNN.US)$ Reuters
1 min ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS

Trytosaveabit

Nov 13 07:03

Hmm! Update

$Clene (CLNN.US)$ Clene Met With FDA on Nov 1 in Type C Meeting to Discuss Potential for Accelerated Approval Pathway in ALS >CLNN
Dow Jones· just

Trytosaveabit

Oct 23 07:34

Update

$Clene (CLNN.US)$ Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.